Dr. Lindsey's Multiple Sclerosis Website

Active Clinical Trials at UT 2018
ACTRIMS Forum 2017
Tecfidera update September, 2016
AAN 2015
AAN 2014
Current Treatments (updated 7/7/13)
Gilenya (updated 4/20/2012)
Tysabri and PML
Recent and current research
Old meetings
New diagnosis of MS
Multiple Sclerosis Basic Information
Interferon versus Glatiramer--update 11/07
Talk on stem cells--2/13/08
About Dr. Lindsey
Research Interests
Clinic information
Contact Us

I attended the annual meeting of the European Committee for Treatment and Research in MS in Berlin from October 10-12, 2018.  This is the largest meeting devoted to MS, with about 10,000 participants, 300 platform presentations, and 1500 poster presentations. 


One focus of this years meeting was progressive MS.  There were a number of talks on the mechanism of damage in progressive MS, and some talks on treatment.  There is currently no treatment which has a marked benefit in progressive MS, and there is increasing interest in finding new treatments for this type of MS along with better ways to measure changes in progressive MS.  A study done in the UK with three drugs already approved for other uses; fluoxetine, amiloride, and riluzole; had negative results. 

Another focus was risk management for current treatments.  Two useful and reassuring presentations reported on death rate and cancer risk with some of the highly effective MS treatments that I currently use.  There was no significant increase in the death rate with rituximab, and there was no signal for an increase in any type of cancer, and in particular no increase in risk of breast cancer with rituximab.  The current label for ocrelizumab raises the question of increased risk of breast cancer, but it seems unlikely that is a real cause and effect relation since it was not seen in the much larger rituximab group.  Rituximab and ocrelizumab are very similar, and I expect they should have the same risks. 

Unlike previous years, there were very few clinical trial results and very few completely new approaches to treatment.  The main exception is the study of the tyrosine kinase inhibitor evobrutinib.  This drug inhibits a protein found in B cells and macrophages that is important for regulation of immune responses.  In the phase II study, it had encouraging results on MRI activity and possibly clinical relapses over 24 weeks.  The phase III study is currently beginning, and this will be an interesting drug to watch. 

My major research interest is the role of Epstein-Barr virus in MS, and there were a few presentations on this topic.  Dr. Olsson reported that a protein called anoctamin-2 cross-reacts with the EBV nuclear antigen, and that a significant fraction of MS patients have an antibody against anoctamin.  Increased antibodies against anoctamin predict risk of MS in the future.  Dr. Klemens reported that in a large cohort of new MS patients from Germany, all persons were infected with EBV.  This supports the idea that infection with EBV is required to get MS.  One poster reported that MS patients with more active disease were more likely to have a high level of antibodies against EBV, and another reported that many of the cytotoxic T cells in MS brain are specific for EBV.   

J. William Lindsey, MD
University of Texas Multiple Sclerosis Research Group
Houston, Texas

copyright 2007-2018 John William Lindsey